# A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins

Source: https://onco.cc/trials/nct07182682/  
OnCo record `nct07182682` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sunvozertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal (Jiangsu) Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery is a phase 3 interventional study registered as NCT07182682 by Dizal (Jiangsu) Pharmaceutical Co., Ltd., with 360 participants planned, started 2025-12-01 and due to reach its primary completion in 2029-09. Interventions recorded: sunvozertinib, Matching Placebo. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07182682
- Phase: 3
- Setting: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Anti-Tumor Efficacy and Safety of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery (WU-KONG16)
- Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT07182682: https://clinicaltrials.gov/study/NCT07182682

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Sunvozertinib](https://onco.cc/drugs/sunvozertinib/)

---
JSON: https://onco.cc/api/v1/entities/nct07182682.json